Search

A recent study from University Hospital in Tunis, Tunisia, highlights the effectiveness of anti-IL-6R therapy, specifically tocilizumab, in treating Takayasu's arteritis. The case study of a 34-year-old patient with refractory Takayasu arteritis showed significant improvement after receiving anti-IL-6R infusions, leading to a complete resolution of symptoms. This research underscores the potential of anti-IL-6R as a promising therapeutic option for Takayasu's arteritis, particularly in cases that are resistant to traditional treatments. [Extracted from the article]

A new report discusses research on Takayasu's arteritis, a condition that affects the blood vessels. The study aimed to compare the effectiveness and safety of two treatments, adalimumab and leflunomide, in patients with Takayasu's arteritis. The study found that both treatments had similar outcomes after 15 months of follow-up. However, only the leflunomide group experienced withdrawal from therapy and mild-to-moderate adverse events. This research provides valuable information for healthcare professionals and patients seeking treatment options for Takayasu's arteritis. [Extracted from the article]

A recent report from the City University of New York (CUNY) provides new insights into central nervous system disorders, specifically systemic vasculitis and headache. Vasculitis refers to inflammation of blood vessels and can lead to injury and disability if left untreated. Headache is an important clue to vasculitic involvement of the central nervous system (CNS). Prompt evaluation and treatment are necessary to prevent progression and cerebral ischemia or infarction. The report highlights progress in the pathogenesis, diagnosis, and treatment of primary adult and pediatric CNS vasculitides. [Extracted from the article]

A recent study conducted at Hacettepe University in Ankara, Turkey, explored the use of biologic agents as treatment options for childhood-onset Takayasu's Arteritis (TA). The study analyzed the medical records of seven patients with TA who received either a TNF-alpha inhibitor (adalimumab) or an IL-6 receptor inhibitor (tocilizumab), and examined the effects of switching between these therapies. The results showed that both TNF-alpha and IL-6 inhibitors were effective in treating childhood-onset TA, but further research is needed to compare their effectiveness through prospective randomized controlled trials. This study provides valuable insights into alternative treatment options for TA in pediatric patients. [Extracted from the article]

Keywords: Beijing; People's Republic of China; Asia; Adrenal Cortex Hormones; Aortic Arch Syndrome; Aortic Diseases and Conditions; Arteritis; Biomarkers; Cardiology; Cardiovascular Diseases and Conditions; Cytokines; Diagnostics and Screening; Drugs and Therapies; Glucocorticoids; Health and Medicine; Immunologic Agents; Immunotherapy; Intercellular Signaling Peptides and Proteins; Membrane Proteins; Monoclonal Antibodies; Pharmaceuticals; Secukinumab Therapy; Takayasu's Arteritis; Tumor Necrosis Factors; Vascular Diseases and Conditions; Vasculitis EN Beijing People's Republic of China Asia Adrenal Cortex Hormones Aortic Arch Syndrome Aortic Diseases and Conditions Arteritis Biomarkers Cardiology Cardiovascular Diseases and Conditions Cytokines Diagnostics and Screening Drugs and Therapies Glucocorticoids Health and Medicine Immunologic Agents Immunotherapy Intercellular Signaling Peptides and Proteins Membrane Proteins Monoclonal Antibodies Pharmaceuticals Secukinumab Therapy Takayasu's Arteritis Tumor Necrosis Factors Vascular Diseases and Conditions Vasculitis 126 126 1 07/10/23 20230711 NES 230711 2023 JUL 10 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- New research on Cardiovascular Diseases and Conditions - Takayasu's Arteritis is the subject of a report. Patients with active TAK who did not respond to treatment with glucocorticoids combined with 2 immunosuppressive agents were treated with either secukinu-mab or TNFi as an add-on therapy without an increased dosage of glucocorticoids. [Extracted from the article]

Aortic Arch Syndrome, Aortic Diseases and Conditions, Arteritis, Biotechnology, Cardiology, Cardiovascular Diseases and Conditions, Drugs and Therapies, Health and Medicine, Immunologic Agents, Immunotherapy, Monoclonal Antibodies, Pharmaceuticals, Risk and Prevention, Takayasu's Arteritis, Tocilizumab Therapy, Vascular Diseases and Conditions, Vasculitis The news editors obtained a quote from the research from Hospital Pitie-Salpetriere: "A total of 109 TAK patients received at least 3 months tocilizumab therapy and were included in this study. Keywords: Aortic Arch Syndrome; Aortic Diseases and Conditions; Arteritis; Biotechnology; Cardiology; Cardiovascular Diseases and Conditions; Drugs and Therapies; Health and Medicine; Immunologic Agents; Immunotherapy; Monoclonal Antibodies; Pharmaceuticals; Risk and Prevention; Takayasu's Arteritis; Tocilizumab Therapy; Vascular Diseases and Conditions; Vasculitis EN Aortic Arch Syndrome Aortic Diseases and Conditions Arteritis Biotechnology Cardiology Cardiovascular Diseases and Conditions Drugs and Therapies Health and Medicine Immunologic Agents Immunotherapy Monoclonal Antibodies Pharmaceuticals Risk and Prevention Takayasu's Arteritis Tocilizumab Therapy Vascular Diseases and Conditions Vasculitis 999 999 1 07/03/23 20230704 NES 230704 2023 JUL 3 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Fresh data on Takayasu's arteritis are presented in a new report. [Extracted from the article]

Adrenal Cortex Hormones, Aortic Arch Syndrome, Aortic Diseases and Conditions, Arteritis, Biotechnology, Cardiology, Cardiovascular Diseases and Conditions, Drugs and Therapies, Glucocorticoids, Health and Medicine, Immunologic Agents, Immunotherapy, Monoclonal Antibodies, Pharmaceuticals, Tocilizumab Therapy, Vascular Diseases and Conditions, Vasculitis, Takayasu's Arteritis Keywords: Adrenal Cortex Hormones; Aortic Arch Syndrome; Aortic Diseases and Conditions; Arteritis; Biotechnology; Cardiology; Cardiovascular Diseases and Conditions; Drugs and Therapies; Glucocorticoids; Health and Medicine; Immunologic Agents; Immunotherapy; Monoclonal Antibodies; Pharmaceuticals; Takayasu's Arteritis; Tocilizumab Therapy; Vascular Diseases and Conditions; Vasculitis EN Adrenal Cortex Hormones Aortic Arch Syndrome Aortic Diseases and Conditions Arteritis Biotechnology Cardiology Cardiovascular Diseases and Conditions Drugs and Therapies Glucocorticoids Health and Medicine Immunologic Agents Immunotherapy Monoclonal Antibodies Pharmaceuticals Takayasu's Arteritis Tocilizumab Therapy Vascular Diseases and Conditions Vasculitis 2023 FEB 20 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- New study results on Takayasu's arteritis have been published. [Extracted from the article]